Research is a key strength for Biogen Idec. Today, Biogen Idec’s goal is to enhance its therapeutic areas of oncology, neurology, dermatology and rheumatology.
Biogen Idec is the world’s third largest biotechnology company, with an R&D; budget expected to exceed $550 million. The company has 1,000 R&D; employees, including approximately 400 in discovery research. The company’s research is closely integrated with its commercial strengths, with leading-edge research in oncology, immunology and neurobiology. Additional discovery and development efforts are aimed at adding substantial value to Biogen Idec’s existing products by extending their use to other diseases.
Biogen Idec has established two Centers of Excellence for its research effort: one in Cambridge, MA and the other in San Diego, CA. This internal capability is supplemented with selective alliances with both other companies and academic research groups aimed at helping Biogen Idec continue to meet the challenges of its future growth.